



USSN: 09/814,357

20/K.T. 3/3 RECEIVED

JAN 31 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name Susan M. Alessi

Signature

Susan M. Alessi

Date

01-23-2003

**AMENDMENT UNDER
37 C.F.R. §1.111**

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket No. CELL-017

Confirmation No. 3927

First Named Inventor YU, DE-CHAO

Application Number 09/814,357

Filing Date March 21, 2001

Group Art Unit 1635

Examiner Name WHITEMAN, BRIAN

Title: "Methods of Treating Neoplasia with Combinations of
Target Cell-Specific Adenovirus, Chemotherapy and
Radiation"

Sir:

This amendment is responsive to the Office Action dated October 23, 2002 for which a three-month period for response was given making this response due on or before January 23, 2003. In view of the amendments to the claims and the remarks put forth below, reconsideration and allowance are respectfully requested.

Please amend the application as follows:

IN THE CLAIMS

Please replace the pending claims with the correspondingly numbered claims below. Claims amended herein are noted by the text in parentheses. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment; captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Cancel claims 61 and 64-71.

59. (amended) A method for suppressing tumor growth in a mammal comprising:

administering a replication competent, target cell-specific adenovirus, said adenovirus comprising an adenoviral early gene essential for replication under transcriptional control of a target cell-specific transcriptional regulatory element (TRE), selected from the group consisting of a prostate-specific antigen (PSA)-TRE, an α -fetoprotein (AFP)-TRE and a human uroplakin II (UPII)-TRE wherein said target cell-specific adenovirus results in virus replication-dependent cytolysis; and